Two more senior executives of multinational pharmaceutical companies may switch to local companies

On December 9, AstraZeneca officially announced to its employees that Yin Min, the head of AstraZeneca’s China Oncology Division, and Wang Dong, the head of the retail division, had decided to leave AstraZeneca to seek external career development opportunities.
The two were working days in AZ.
Will end on the 31st of this month
.
It is understood that Yin Min joined AstraZeneca China in September 2006 and has served as chief financial officer and compliance officer for Greater China
.
Since June 2018, he has served as the general manager of China Oncology Division
.
Wang Dong joined AstraZeneca China in 2015 and is responsible for business development and team management of the company's full products in the retail channel
.
Since 2019, the retail market of AstraZeneca has continued to develop, helping AstraZeneca gain a dominant position in the retail industry
.
In AstraZeneca’s announcement to employees, AstraZeneca has not yet announced Yin Min’s successor after his resignation, but before the successor arrives, the Oncology Division is temporarily led by President Wang Lei
.
Li Baiyang, the current acting marketing director of AstraZeneca's national retail marketing department, will be promoted to executive director and person in charge, responsible for the retail business, and will directly report to the vice president, chief marketing officer, business strategy and operational excellence department head of AstraZeneca China, And the county’s chronic disease business and community business leaders report
.
It is worth mentioning that since July this year, AstraZeneca China's executives have frequently "leaved", and many of them have gone to local pharmaceutical companies
.
For example, on November 3, Du Haochen, vice president of AstraZeneca China and head of the county business department, decided to leave the company due to personal reasons
.
On November 18th, Du Haochen officially joined BeiGene as the head of the broad market
.
According to industry sources, after the two leave AstraZeneca this time, they will also join two domestic pharmaceutical companies
.
In fact, it has long been common for executives of multinational pharmaceutical companies to switch to local pharmaceutical companies.
Since this year alone, a large number of executives of multinational pharmaceutical companies have joined domestic pharmaceutical companies
.
For example, in October, Dr.
Joseph E.
Eid, an expert in the medical field, officially announced that he had joined Hengrui Pharmaceuticals as executive vice president, chief medical officer and head of global drug development.

.
It is reported that Dr.
Joseph E.
Eid, as a medical oncologist and hematologist, has more than 20 years of experience in clinical development and medical affairs in the academic medicine and biopharmaceutical industries
.
In addition, before joining Hengrui, Dr.
Joseph E.
Eid also held senior management positions in many multinational pharmaceutical companies such as Roche, Merck, Bristol-Myers Squibb
.
On the same day, Beijing Danxu Biopharmaceutical Co.
, Ltd.
announced that it had hired Shi Qian as the company's CEO to be responsible for all tasks of Danxu
.
Before joining Danxu Biotechnology, Dr.
Shi Qian was the general manager and head of scientific research of Apollomics China
.
Going forward to July, Medicilon also announced the appointment of Dr.
Xuedong Dai as Executive Vice President of Medicilon International R&D Services
.
Before joining Medicilon, Dai Xuedong served as an executive in Xi'an Janssen, Huiyuan Biotechnology, GSK, Xenoport and other domestic and foreign pharmaceutical companies and CROs.
.
.
Analysis shows that from the above and the recent two years of multinational pharmaceutical companies flow , The flow of executives of multinational corporations has obviously accelerated
.
This may be due to the drastic changes in the domestic pharmaceutical industry, and the large-scale adjustments of multinational pharmaceutical companies in China's strategy and talent structure; and the continuous improvement of the domestic pharmaceutical industry requires a large number of executives with international perspectives to lead the way, so more generous conditions have been set , Caused by the continuous return of foreign medical talents
.
In the future, with the rapid development of the local pharmaceutical industry and enterprises, the advantages of foreign companies are no longer obvious, and the generous treatment provided by domestic companies, the number of executives of multinational pharmaceutical companies leaving their jobs to enter local innovative pharmaceutical companies may continue to increase
.
It is worth noting that at the same time, the competition between the two sides for high-level talents is expected to intensify
.